A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia

Phase 2

Completed

• Conditions: Lymphocytic Leukemia, Chronic
• Interventions: Drug: Bevacizumab

• Registration Number: NCT00754650
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with Avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. Patients received 8 cycles (21 days duration) of Avastin monotherapy (15mg/kg) with 6 months of follow-up.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-09-17
• Study First Submitted QC: 2008-09-17
• Study First Posted: 2008-09-18
• Primary Completion: 2009-03
• Study Completion: 2009-03
• Status Verified: 2014-05
• Results First Submitted: 2014-05-27
• Results First Submitted QC: 2014-05-27
• Last Update Submitted: 2014-05-27
• Results First Posted: 2014-06-26
• Last Update Posted: 2014-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Male or female patients, ≥ 18 years of age.
• B-chronic lymphocytic leukemia not yet requiring treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• No previous treatment of chronic lymphocytic leukemia (CLL) by chemotherapy, radiotherapy, or immunotherapy.
• Life expectancy > 6 months.

Exclusion Criteria

• Central nervous system (CNS) involvement by lymphoma or any evidence of spinal cord compression.
• Computed tomography (CT) scan based evidence of tumor invading major blood vessels.
• Gastrointestinal (GI) tract involvement by CLL.
• Active viral, bacterial, or fungal infection.
• Uncontrolled hypertension, cerebrovascular accident/stroke (≤ 6 months prior to randomization), myocardial infarction (≤ 6 months prior to randomization), unstable angina (≥ New York Heart Association (NYHA) Grade IV), thrombosis within 6 months before enrollment, NYHA Grade II congestive heart failure, or serious cardiac arrhythmia requiring ongoing medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Bevacizumab 15 mg/kg	Bevacizumab	Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.

Primary Outcome Measures

Name	Time	Method
Bone Marrow Response	Baseline to the end of treatment (up to 24 weeks)	Bone marrow response was defined as the change in percentage of infiltration at the interim staging (after 4 cycles of treatment) and the end of treatment.

Secondary Outcome Measures

Name	Time	Method
Best Overall Response (BOR)	Baseline to the end of treatment (up to 24 weeks)	The percentage of participants in each BOR category (complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD)) is reported. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions.